|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Non-interest-bearing cash | ||||||||||||||||||||
| Interest-bearing cash and due from banks | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Investment securities: | ||||||||||||||||||||
| Securities available-for-sale, at fair value (amortized cost of $49,442 and $53,517, respectively) | ||||||||||||||||||||
| Securities held-to-maturity (fair value of $19,318 and $13,567, respectively) | ||||||||||||||||||||
| Loans receivable, net of unearned income | ||||||||||||||||||||
| Allowance for credit losses | ||||||||||||||||||||
| Loans receivable, net | ||||||||||||||||||||
| Accrued interest receivable | ||||||||||||||||||||
| Foreclosed assets | ||||||||||||||||||||
| Premises and equipment, net | ||||||||||||||||||||
| Stock in correspondent banks, at cost | ||||||||||||||||||||
| Bank-owned life insurance | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| TOTAL ASSETS | ||||||||||||||||||||
| LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Deposits | ||||||||||||||||||||
| Non-interest-bearing | ||||||||||||||||||||
| Interest-bearing | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| Borrowings | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| TOTAL LIABILITIES | ||||||||||||||||||||
| SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock, $0.01 par value - 30,000,000 shares authorized; 4,034,091 and 4,074,911 issued and outstanding, respectively | ||||||||||||||||||||
| Additional paid-in capital | ||||||||||||||||||||
| Unallocated common stock held by Employee Stock Ownership Plan ("ESOP") | ||||||||||||||||||||
| Unallocated common stock held by benefit plans | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| TOTAL SHAREHOLDERS' EQUITY | ||||||||||||||||||||
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY | ||||||||||||||||||||
Loading...
